About
Rezera Inc.
Rezera is a clinical-stage biotechnology company developing a portfolio of internally invented, proprietary and wholly-owned oral inhibitors of NOD-like receptor protein 3, or NLRP3.
We have been a leader in the research, discovery and development of NLRP3 inhibitors for over a decade, and we have designed our portfolio to address historical challenges faced by other NLRP3 inhibitors: potency, therapeutic index and tissue penetration.
Our lead product candidate, ruvonoflast, is highly potent, has been observed to be well tolerated in five completed human clinical trials and in an extensive nonclinical toxicology program, and is designed to achieve broad tissue distribution, including penetration into the central nervous system, or CNS.
Rezera Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Financial Highlights
Historical financial performance
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| S-1 | Oct 21, 2026 | General form for registration of securities under the Securities Act of 1933 |
| DRS/A | Sep 22, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS/A | Aug 21, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS | Jul 7, 2026 | [Cover] Draft Registration Statement |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Geoffrey McDonough, M.D.
President, Chief Executive Officer and Director
Chris Guiffre, J.D., M.B.A.
Chief Financial Officer
Jyothis George, MBBS, Ph.D.
Chief Medical Officer
Alan P. Watt, Ph.D., M.B.A.
Chief Scientific Officer
Nicholas Clarke, Ph.D.
Chief Development Officer
Donald Nicholson, Ph.D.
Chairman of the Board
Elisabeth Björk, Ph.D.
Director
Alex Pasteur, Ph.D.
Director
Kevin Raidy
Director
Henrijette Richter, Ph.D.
Director
